Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 10/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.36 |
| ▸ | RPS6KA1 | Q15418 | 5/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022965 | 0.86 | PIM1 (0.35) | MAPK3CCNT1IRAK4CDK2 | |
| SCHEMBL2021524 | 0.82 | PDE10A (0.46) | PDE4DPDE4BCCNE1CDK2 | |
| SCHEMBL2022500 | 0.77 | MMP1 (0.32) | — | |
| SCHEMBL3236457 | 0.76 | MAPK1 (0.37) | MAPK1MAPK3RPS6KA1CCNT1HDAC3 | |
| SCHEMBL2019860 | 0.72 | PDE4D (0.39) | MAPK1MAPK3RPS6KA1PDE4DCCNT1 | |
| SCHEMBL28624228 | 0.72 | IDH1 (0.35) | MAPK1PDE4DCCNT1 | |
| SCHEMBL3199851 | 0.69 | OPRK1 (0.51) | MAPK1CCNT1 | |
| SCHEMBL3713155 | 0.69 | TDP1 (0.41) | MAPK1MAPK3RPS6KA1CCNT1PDE4B | |
| SCHEMBL2020522 | 0.68 | KMT2A (0.36) | — | |
| SCHEMBL12574434 | 0.67 | MAPK1 (0.47) | MAPK1MAPK3CCNT1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350027-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE10A, PDE12, PDE9A | MAPK1 985/4885MAPK3 1907/4885RPS6KA1 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.